Does Rallies show Form 4 insider transactions for MIST?

Yes. Rallies tracks MIST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MIST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MIST. It does not provide personalized investment advice.

MIST (Milestone Pharmaceuticals Inc. Common Shares) Stock Analysis - Insider Trades

Milestone Pharmaceuticals Inc. Common Shares (MIST) is a publicly traded Healthcare sector company. As of May 21, 2026, MIST trades at $1.48 with a market cap of $181.77M and a P/E ratio of -2.00. MIST moved +4.90% today. Year to date, MIST is -25.74%; over the trailing twelve months it is +7.91%. Its 52-week range spans $0.63 to $3.06. Analyst consensus is strong buy with an average price target of $7.25. Rallies surfaces MIST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MIST stock inside the company?

Recent MIST insider activity includes Oliveto Joseph sold 36.50K, Bharucha David sold 12.24K, Nelson Jeffrey Edward sold 12.24K, Muller Lorenz sold 11.18K, and Hasija Amit sold 12.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MIST Key Metrics

Key financial metrics for MIST
Metric	Value
Price	$1.48
Market Cap	$181.77M
P/E Ratio	-2.00
EPS	$-0.75
Dividend Yield	0.00%
52-Week High	$3.06
52-Week Low	$0.63
Volume	19
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-63.06M
Gross Margin	0.00%

Recent MIST Insider Trades

Oliveto Joseph sold 36.50K (~$82.49K) on Apr 16, 2026.
Bharucha David sold 12.24K (~$23.63K) on Jan 26, 2026.
Nelson Jeffrey Edward sold 12.24K (~$23.63K) on Jan 26, 2026.
Muller Lorenz sold 11.18K (~$21.58K) on Jan 26, 2026.
Hasija Amit sold 12.24K (~$23.63K) on Jan 26, 2026.

Latest MIST News

Milestone Pharmaceuticals Posts $26.1M Q1 Loss, $238K CARDAMYST Revenue — May 13, 2026
Milestone Pharmaceuticals Shares Plunge After Q1 CARDAMYST Revenue Misses Forecast — May 13, 2026
Milestone Pharmaceuticals Posts $0.2M Q1 Sales, $184M Cash Runway — May 13, 2026
Milestone Launches Phase 4 PSVT Registry to Enroll 450 Patients Across 20 Sites — Apr 10, 2026
Milestone’s CARDAMYST Added to Express Scripts National Formularies Effective March 27, 2026 — Mar 31, 2026

MIST Analyst Consensus

4 analysts cover MIST: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.25.

Common questions about MIST

Who is trading MIST stock inside the company?: Recent MIST insider activity includes Oliveto Joseph sold 36.50K, Bharucha David sold 12.24K, Nelson Jeffrey Edward sold 12.24K, Muller Lorenz sold 11.18K, and Hasija Amit sold 12.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MIST?: Yes. Rallies tracks MIST insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MIST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MIST. It does not provide personalized investment advice.